Rituximab in rheumatoid arthritis and the risk of malignancies: Report from a French cohort

Joint Bone Spine

Volumn 78, Issue 5, 2011, Pages 484-487

  Slimani, Samy ^a   Lukas, Cédric ^a   Combe, Bernard ^a   Morel, Jacques ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

Malignancy; Rheumatoid arthritis; Rituximab

Indexed keywords

GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE; RITUXIMAB;

ADULT; AGED; ARTICLE; BONE CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGRESSION; CANCER RISK; COHORT ANALYSIS; COLON CANCER; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OROPHARYNX CANCER; OUTCOME ASSESSMENT; OVARY CANCER; PROSTATE CANCER; RECURRENT CANCER; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 80053455476     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.11.012     Document Type: Article

References (23)

1. Colombat P., Salles G., Brousse N., et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001, 97:101-106.
2. Colombat P., Brousse N., Morschhauser F., et al. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analysis with extended follow-up (F/up) of 7 years. Blood 2006, 108:486.
3. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
4. Emery P., Fleischmann R., Filipowicz-Sosnowska A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006, 54:1390-1400.
5. Cohen S.B., Emery P., Greenwald M.W., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806.
6. Toussirot E., Pertuiset E., Sordet C., et al. Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice. Joint Bone Spine 2010, 77:142-145.
7. Keystone E., Fleischmann R., Emery P., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007, 56:3896-3908.
8. van Vollenhoven R, Emery P, Bingham C, et al. Extended follow-up of the long-term safety of rituximab in rheumatoid arthritis. Ann Rheum Dis 2007;66:88 [abstract].
9. Reff M.E., Carner K., Chambers K.S., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
10. Tetreault S., Abler S.L., Robbins B., et al. Peripheral T-cell lymphoma after anti-CD20 antibody therapy. J Clin Oncol 1998, 16:1635-1637.
11. Micallef I.N., Kirk A., Norton A., et al. Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma. Blood 1999, 93:2427-2428.
12. Maloney D.G., Davis T., Levy R. Peripheral T-cell lymphoma after anti-CD20 antibody therapy. J Clin Oncol 1998, 16:1636-1637.
13. Hemminki K., Li X., Sundquist K., et al. Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology 2008, 47:698-701.
14. Parikh-Patel A, White RH, Allen M, et al. Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control 2009;20:1001-10.
15. Mellemkjaer L., Linet M.S., Gridley G., et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996, 32A:1753-1757.
16. Cibere J.C., Sibley J., Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997, 40:1580-1586.
17. Wolfe F., Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004, 50:1740-1751.
18. Kanik K.S., Cash J.M. Does methotrexate increase the risk of infection or malignancy?. Rheum Dis Clin N Am 1997, 23:955-967.
19. Buchbinder R., Barber M., Heuzenroeder L., et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 2008, 59:794-799.
20. Askling J., Fored C.M., Brandt L., et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005, 64:1421-1426.
21. Wolfe F., Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy. Analyses from a large us observational study. Arthritis Rheum 2007, 56:2886-2895.
22. Geborek P., Bladström A., Turesson C., et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005, 64:699-703.
23. Askling J, Baecklund E, Granath F et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009;68:648-653.